Melatonin Encyclopedia — Scientific Background

What Is Melatonin?

Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine neurohormone synthesized primarily in the pineal gland from the essential amino acid tryptophan. It is a hormone produced by the pineal gland that regulates circadian rhythms and is involved in the synchronization of the sleep-wake cycle to the daily light-dark cycle. Melatonin is a modified tryptophan with potent biological activity, exerted by stimulation of specific plasma membrane MT1/MT2 receptors.

Biosynthesis and Secretion

Melatonin is synthesized from the essential amino acid tryptophan through a series of enzymatic reactions. Physiologically, melatonin secretion rises shortly after darkness onset, peaks between 02:00 and 04:00, and declines during the latter half of the night. The highest value of melatonin secretion is nearly diametrically opposed to maximum daylight intensity, with daylight serving as the primary stimulus for maintaining the circadian rhythm of melatonin secretion.

Mechanisms of Action

MT1 and MT2 Receptor-Mediated Effects

Most actions of melatonin are mediated by membrane receptors and nuclear sites. Two of these receptors, MT1 and MT2, are members of the 7-transmembrane G-protein-coupled receptor (GPCR) family. The hormone acts in a dual way, resetting the clock via MT2 receptor and suppressing neuronal firing via MT1 receptor. Melatonin inhibits the activity of neurons in the suprachiasmatic nucleus (SCN) of the hypothalamus, the master circadian pacemaker in the mammalian brain. Neuroanatomic evidence suggests that many of the effects of melatonin on circadian rhythms involve actions on MT1 receptors in the SCN, retina, and pars tuberalis of the adenohypophysis.

MT3 Receptor and Cellular Detoxification

A third receptor in mammals, MT3, is not a G-protein-coupled receptor but instead a high-affinity binding site on the cytosolic enzyme quinone reductase 2 that is involved in cellular detoxification; this might explain some of melatonin's effects as an antioxidant.

Receptor-Independent Antioxidant Mechanisms

Melatonin exerts its antioxidant effects directly and indirectly. Due to its dual lipophilic and hydrophilic properties, this indoleamine crosses all the barriers within the body and plays an important role in the expression of genes involved in the production of free radicals. Melatonin is a major scavenger of both oxygen and nitrogen-based reactive molecules. Its metabolites can also detoxify free radicals and derivatives. The lipophilic nature of melatonin favors the indolamine crossing cell membranes to easily reach subcellular compartments including mitochondria, where it interacts with lipid bilayers and stabilizes mitochondrial inner membranes.

Clinical Evidence

Sleep Quality and Insomnia

A meta-analysis of 19 studies (1,683 patients) found that in children and adults, melatonin for treatment of primary sleep disorders decreases time to fall asleep by 7 minutes, increases overall sleep time by 8 minutes, and improves sleep quality. A systematic review and meta-analysis of randomized controlled trials in delayed sleep-wake phase disorder demonstrated that exogenous melatonin improves sleep quality, including wakefulness after sleep onset and sleep onset latency (z=−4.94, p<0.0001), total sleep time (z=3.72, p=0.0002), and shifts sleep timing (z=−8.80, p<0.0001).

Parkinson‘s Disease Sleep Disturbances

A systematic review and meta-analysis of randomized placebo-controlled trials evaluated melatonin in Parkinson’s disease patients. Seven studies entered the meta-analysis, which showed melatonin improved sleep quality and insomnia, as indicated by the Pittsburgh Sleep Quality Index (PSQI) (MD=−1.75 [−2.94 to −0.55]; p=0.004) and Epworth Sleepiness Scale (ESS) (MD=−1.07 [−1.87 to −0.27]; p=0.009). Sleep onset latency (MD=−9.74 [−17.47 to −2.02]; p=0.001) and total sleep time (SMD=0.84 [0.47 to 1.21]; p<0.00001) improved, favoring melatonin. Melatonin was well-tolerated, with minimal side effects reported.

Shift Work and Jet Lag

A Cochrane systematic review of pharmacological interventions for sleepiness and sleep disturbances caused by shift work found low-quality evidence that melatonin (1 to 10 mg) after the night shift may increase sleep length during daytime sleep by 24 minutes and night-time sleep by 17 minutes, compared to placebo. Clinical studies have shown that melatonin, when taken near local bedtime (22:00 to midnight), reduces jet lag on flights crossing 5 or more time zones.

The Bioavailability Challenge

Despite its broad physiological activity, melatonin presents significant formulation challenges. The compound undergoes extensive first-pass hepatic metabolism and has a short half-life, resulting in extremely low oral bioavailability of approximately 15%. Clinical use of melatonin has relied on oral administration, which in many cases is hampered by low and variable bioavailability.

A pharmacokinetic study comparing Liposomal Melatonin and nanoemulsion formulations found that encapsulation in nanoparticles provides prolonged release when melatonin is solubilized in nanoparticles, with T1/2 of 81 minutes for melatonin-liposomes versus 50 minutes for nanoemulsion and 26 minutes for melatonin-ethanol solution. The pharmacokinetic parameters were confirmed in vivo in adult rats as similar melatonin levels detected in blood and indicated higher bioavailability in brain after intravenous administration of melatonin nanoformulations (10 mg/kg) in comparison to the free-melatonin administration.

liposomal Melatonin

Liposomal encapsulation of melatonin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the melatonin molecule, forming a protective shell that enhances absorption and bioavailability. This delivery system:

• Protects melatonin from first-pass hepatic metabolism by CYP1A2 enzymes

• Enhances intestinal absorption through lipid-mediated pathways

• Provides sustained release with prolonged half-life

• Improves delivery across the blood-brain barrier

Liposomal melatonin formulations have been developed for both oral and injectable applications. An organic solvent-free injectable formulation using FDA-approved components demonstrated improved melatonin solubilization in water (2.6 mg/mL) and prolonged release kinetics. Flexible liposomes encapsulating melatonin have been developed for transdermal application, with pharmacokinetic experiments in rats showing that the AUC of the flexible liposome is improved by 1.82 times compared with common liposomes, indicating enhanced bioavailability of melatonin absorbed through skin.

Safety and Regulatory

Melatonin is generally well tolerated at physiological and supplemental doses. At lower doses (approximately 0.3–5 mg), melatonin is generally well tolerated and associated with minimal adverse effects. Daily doses of up to 300 mg melatonin without any clinically significant side effects have been reported in the literature. The recommended dose is 0.5–5 mg for a maximum of 5 days for certain indications. Doses of 10 mg or higher have raised concerns regarding potential long-term endocrine disruption, including suppression of endogenous melatonin secretion, and further investigation is needed into the long-term use of melatonin in individuals with hepatic or renal impairment. A systematic review and meta-analysis of randomized controlled trials has reported improved reproductive outcomes when melatonin is used as an adjunct in assisted reproductive technologies.

In some countries, melatonin is considered a drug and is regulated as such. Melatonin is widely commercialized as a dietary supplement ingredient in the United States, Europe, and other regions. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

169$/KG

149$/KG